Literature DB >> 27488277

Behavior of chemiluminescent assays to measure serum testosterone during androgen deprivation therapy.

Juan Morote1,2, Inma Comas3,2, Jacques Planas1,2, Ana Celma1,2, Roser Ferrer3,2, Lucas Regis4,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27488277     DOI： 10.1111/iju.13180

Source DB:  PubMed          Journal:  Int J Urol        ISSN： 0919-8172            Impact factor:   3.369


× No keyword cloud information.
  4 in total

1.  Testosterone suppression in the treatment of recurrent or metastatic prostate cancer - A Canadian consensus statement.

Authors:  Laurence Klotz; Bobby Shayegan; Chantal Guillemette; Loretta L Collins; Geoffrey Gotto; Dominique Guérette; Marie-Paule Jammal; Tom Pickles; Patrick O Richard; Fred Saad
Journal:  Can Urol Assoc J       Date:  2017-12-19       Impact factor: 1.862

Review 2.  Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerations.

Authors:  E David Crawford; Axel Heidenreich; Nathan Lawrentschuk; Bertrand Tombal; Antonio C L Pompeo; Arturo Mendoza-Valdes; Kurt Miller; Frans M J Debruyne; Laurence Klotz
Journal:  Prostate Cancer Prostatic Dis       Date:  2018-08-21       Impact factor: 5.554

3.  Serum Luteinizing Hormone Testing Can Identify Optimal Medical Castration.

Authors:  Juan Morote; Imma Comas; Roser Ferrer; Lucas Regis; Anna Celma; Anna Santamaría; Jacques Planas; Enrique Trilla
Journal:  Eur Urol Open Sci       Date:  2020-06-22

Review 4.  Definition of Castrate Resistant Prostate Cancer: New Insights.

Authors:  Juan Morote; Adriana Aguilar; Jacques Planas; Enrique Trilla
Journal:  Biomedicines       Date:  2022-03-17
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.